Advances in systemic therapy for metastatic breast cancer: future perspectives

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

(2017) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

(2016) Kathy Miller et al.   BMC CANCER

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

(2016) Sarat Chandarlapaty et al.   JAMA Oncology

Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

(2015) Sara M Tolaney et al.   CANCER RESEARCH

Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

(2015) Leisha A. Emens et al.   CANCER RESEARCH

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

(2013) Yasmin Issa-Nummer et al.   PLoS One

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

(2013) Srikanth Nagalla et al.   GENOME BIOLOGY

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Beyond trastuzumab: New treatment options for HER2-positive breast cancer

(2011) Kamal S. Saini et al.   BREAST

Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

(2011) J Baselga et al.   CANCER RESEARCH

Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer

(2011) G.S. Bhattacharvva et al.   EUROPEAN JOURNAL OF CANCER

Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer

(2008) D. Generali et al.   CLINICAL CANCER RESEARCH